SquareMind raises $18M for robotic skin imaging

SquareMind, a Paris-based medical robotics company developing dermatology imaging systems, announced $18 million in financing, including an earlier pre-Series A round, as it prepares to launch Swan in the United States and Europe.

Sonder Capital and the French government’s Deep Tech 2030 fund, managed by Bpifrance, co-led the financing, with participation from Adamed, Calm/Storm Ventures and Teampact Ventures. SquareMind says the funding will support commercial, engineering and customer support hiring ahead of Swan’s commercial launch.

Swan is a robotic full-body skin imaging platform designed to capture standardized dermoscopic-level images across the skin surface. The patient stands in front of the system while a robotic arm moves around the body and captures images in a short, contactless session, giving dermatologists a structured visual record that can be reviewed and compared over time.

Skin examinations require consistent imaging and comparison of small changes between visits. SquareMind automates image acquisition to create a full-body record for clinicians.

Swan is paired with AI-based software to support review and help track new or changing moles over time, but the company describes the physician as retaining clinical judgment.

The company says Swan is FDA-listed and CE-marked.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to [email protected] or reach out on X at @agkorthos.